New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 16, 2013
08:29 EDTONXXOnyx Pharmaceuticals price target lowered to $96 from $99 at RW Baird
Baird lowered its price target on Onyx Pharmaceuticals to reflect the dilutive nature of its secondary offering. The firm has no change to its positive stance and remains buyers of the shares citing bullish signals from its recent Kyprolis survey which is expected to ramp in 2013. Shares are Outperform rated.
News For ONXX From The Last 14 Days
Check below for free stories on ONXX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 26, 2014
08:04 EDTONXXOnyx treatment of Waldenstrom's macroglobulinemia granted orphan status
Oprozomib was granted FDA orphan drug designation as a treatment of Waldenstrom's macroglobulinemia, the agency stated. Reference Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use